NCT00003707已完成1 期
A Phase I, Maximum Tolerated Dose (MTD) Trial to Determine the Safety and Pharmacokinetics of Chronic Oral Administration of Farnesyl Transferase Inhibitor R115777 in Combination With Gemcitabine in Subjects With Advanced Incurable Cancer
The University of Texas Health Science Center at San Antonio1 个研究点 分布在 1 个国家目标入组 22 人开始时间: 1998年10月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 22
- 试验地点
- 1
研究概览
简要总结
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
PURPOSE: Phase I trial to study the effectiveness of combining R115777 with gemcitabine in treating patients with advanced cancer.
详细描述
OBJECTIVES:
- Determine the maximum tolerated dose and dose limiting toxicities of tipifarnib in combination with gemcitabine in patients with advanced cancer.
- Investigate potential pharmacokinetic interactions between tipifarnib and gemcitabine in these patients.
- Determine the efficacy of this regimen in patients with measurable or evaluable disease.
- Evaluate the quality of life of these patients.
OUTLINE: This is a dose-escalation study of tipifarnib.
Patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15 and oral tipifarnib every 12 hours beginning on day 2. Treatment continues every 4 weeks in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients each receive escalating doses of tipifarnib until the maximum tolerated dose (MTD) is reached. The MTD is defined as the dose at which fewer than one third of the patients experience dose limiting toxicity.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Pathologically proven advanced cancer for which no curative therapy exists
- •PATIENT CHARACTERISTICS:
- •18 and over
- •Performance status:
- •Life expectancy:
- •Not specified
- •Hematopoietic:
- •Absolute neutrophil count greater than 1,500/mm^3
- •Platelet count greater than 100,000/mm^3
- •Hemoglobin greater than 9 g/dL
- •Bilirubin normal
- •SGOT and SGPT no greater than 2 times upper limit of normal (ULN) (no greater than 5 times ULN if liver metastases present)
- •Creatinine normal
- •Unassisted oral or enteral intake sufficient to maintain a reasonable state of nutrition
- •No concurrent medical condition that is likely to interfere with study participation
- •No active visual disturbances that require intervention beyond corrective lenses
- •Not pregnant or nursing
- •Negative pregnancy test
- •Fertile patients must use effective contraception
- •PRIOR CONCURRENT THERAPY:
- •Biologic therapy:
- •No prior bone marrow transplantation
- •No concurrent immunotherapy
- •Chemotherapy:
- •At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)
- •No prior high dose chemotherapy with bone marrow or stem cell rescue
- •No other concurrent chemotherapy
- •Endocrine therapy:
- •No concurrent hormone therapy (except megestrol acetate)
- •Radiotherapy:
- •At least 4 weeks since prior radiotherapy
- •No prior radiotherapy to 25% or more of bone marrow
- •No concurrent radiotherapy (except palliative radiotherapy within the first 28 days of the study)
- •Not specified
- •At least 30 days since prior investigational therapy
- •No concurrent investigational therapy
排除标准
- 未提供
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Azacitidine Plus Phenylbutyrate in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous TreatmentSmall Intestine CancerUnspecified Adult Solid Tumor, Protocol SpecificLymphomaNCT00005639Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins34
已完成
1 期
Irinotecan Plus Raltitrexed in Treating Patients With Refractory Solid TumorsUnspecified Adult Solid Tumor, Protocol SpecificNCT00003109Fox Chase Cancer Center39
已完成
1 期
Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic CancerEndometrial CancerFallopian Tube CancerOvarian CancerCervical CancerSarcomaNCT00032162AGO Study Group63
Unknown
1 期
Liposomal Daunorubicin in Treating Patients With Metastatic Breast CancerBreast CancerNCT00004207University of Leicester
已完成
1 期
CCI-779 in Treating Patients With Advanced Solid TumorsBrain and Central Nervous System TumorsMetastatic CancerUnspecified Adult Solid Tumor, Protocol SpecificNCT00003712The University of Texas Health Science Center at San Antonio15